Dinalbuphine Sebacate in Postoperative Pain Control After TKA

Effectiveness of Dinalbuphine Sebacate in Postoperative Pain Control Following Total Knee Arthroplasty: A Randomized Double Blinded Placebo-controlled Trial

To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty

A single dose of intramuscular Dinalbuphine Sebacate can mitigate pain for up to 1 week after TKA

Inclusion Criteria:

• Osteoarthritic knee patients underwent unilateral primary TKA
• Age 50-90 years
• ASA class I-III
• Participants understand and consent to the protocol of the trial

Exclusion Criteria:

• Morbid obesity (BMI>40)
• Knee osteoarthritis from inflammatory knee arthritis, trauma, infection
• Previous knee surgery
• Cognitive disorder
• Liver disease
• Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate
• CYP3A4 inhibitor and inducer drugs used